Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2015 Nov 23;7(4):5844.
doi: 10.4081/hr.2015.5844.

The Anti-Factor Xa Range For Low Molecular Weight Heparin Thromboprophylaxis

Matthew Y Wei  1 , Salena M Ward  1
Affiliations
Review

The Anti-Factor Xa Range For Low Molecular Weight Heparin Thromboprophylaxis

Matthew Y Wei et al. Hematol Rep. .

Abstract

Low molecular weight heparins (LMWHs) are now the mainstay option in the prevention and treatment of venous thromboembolism. In some patients receiving therapeutic doses of LMWH, activity can be measured by quantifying the presence of Anti-factor Xa (AFXa) for dose adjustment. However, currently there are no guidelines for LMWH monitoring in patients on thromboprophylactic, doses, despite certain patient populations may be at risk of suboptimal dosing. This review found that while the AFXa ranges for therapeutic levels of LMWHs are relatively well defined in the literature, prophylactic ranges are much less clear, thus making it difficult to interpret current research data. From the studies published to date, we concluded that a reasonable AFXa target range for LMWH deep venous thromboses prophylaxis might be 0.2-0.5 IU/mL.

Keywords: Low molecular weight heparin; anti-factor Xa; venous thromboembolism.

PubMed Disclaimer

Conflict of interest statement

Conflict of interest: the authors declare no potential conflict of interest.

References

    1. Hirsh J, Warkentin TE, Shaughnessy SG, et al. Heparin and low-molecular-weight heparin: mechanisms of action, pharmacokinetics, dosing, monitoring, efficacy, and safety. Chest 2001;119:64S-94S. - PubMed
    1. Geerts WH, Bergqvist D, Pineo GF, et al. Prevention of venous thromboembolism: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008;133:381S-453S. - PubMed
    1. Nutescu EA, Spinler SA, Wittkowsky A, Dager WE. Low-molecular-weight heparins in renal impairment and obesity: available evidence and clinical practice recommendations across medical and surgical settings. Ann Pharmacother 2009;43:1064-83. - PubMed
    1. Lim W. Using low molecular weight heparin in special patient populations. J Thromb Thrombolysis 2010;29:233-40. - PubMed
    1. Barras M. Anti-Xa assays. Australian Prescriber 2013;36:4.